摘要
目的探讨吡柔比星(THP)膀胱内灌注预防浅表性膀胱癌术后复发的有效性及安全性。方法符合入选标准的98位患者随机分成三组于手术后2周内开始行吡柔比星膀胱灌注,三组的保留灌注时间分别为30min,1、2h。20mg/次,每周1次共8次;以后每个月1次共1年,定期膀胱镜检查进行随访。结果98例浅表性膀胱移行细胞癌患者,术后平均随访时间(11.8±6.83)个月。三组无肿瘤复发率分别为82.36%、80.00%、82.76%,复发率为17.64%、20.00%、17.24%,三组之间差异无显著性;三组的尿路刺激症状发生率分别为35.29%、51.42%、58.62%;全身症状发生率为5.88%、11.43%、24.14%。其中在2h组有4例因为尿路刺激症状及全身症状严重,不能耐受,暂停灌注,其余患者均完成治疗。结论THP膀胱内保留灌注30min预防膀胱癌术后复发的疗效满意,患者耐受性好,副作用少。
Objective To investigate the efficacy and safety of intravesical instillation of pirarubicin（THP） for preventing postoperative recurrence of superficial bladder cancer. Methods 98 Patients with superficial transitional cell bladder cancer who met inclusion criteria were enrolled in this study. 98 patients were div/ded into three groups ： 30min group, lh group and 2h group, THP （20 mg/50 ml of nonnal saline） was instilled intravesically w/th/n two weeks after operation once a week for eight weeks, followed by once a month till one year. Regular cystoscopy was performed for the follow - up. Results All the patients were followed up for an average time of 11.8 ± 6.83 months. Tumor recurrence rate were 17.64%, 20.00%, 17.24%, there was no significant difference among them . LUTS rate were 35.29% ,51.42% ,58.62% ; general symptom rate were 5.88% ,11.43% ,24.14% .4 cases in 2h group withdrew the treatment for not being able to tolerate LUTS and general symptom. Conedusion 30rain lntravesical administration of THP for 30 rain after operation was effective and well - tolerated for preventing tumor recurrence.
出处
《浙江临床医学》
2007年第2期159-160,共2页
Zhejiang Clinical Medical Journal
关键词
吡柔比星
膀胱肿瘤
膀胱灌注
Pirarubicin ；Bladder Cancer ；Intravesical Instillation
